Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.

Background: Most patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plus alum.

Dendritic cell counts in the peripheral blood of healthy adults.

The normal range for adult blood dendritic cells (DC) has not been established. Blood DC counts were assayed directly from blood for 16 female and 11 male healthy adults with an age range of 22-60 years old (median, 46 years). DC were defined as lineage 1-negative/dim, CD34-negative/dim, and HLA-DR-positive within the total peripheral blood leukocyte (PBL) population.